NASDAQ:HTBX - Heat Biologics Stock Price, Price Target & More

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Shares of Heat Biologics reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

Heat Biologics (NASDAQ:HTBX) issued its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.70) by $0.05. The biopharmaceutical company earned $0.75 million during the quarter. Heat Biologics had a negative return on equity of 182.19% and a negative net margin of 543.30%. View Heat Biologics' Earnings History.

Heat Biologics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Heat Biologics.

2 equities research analysts have issued 1-year target prices for Heat Biologics' stock. Their forecasts range from $22.50 to $22.50. On average, they anticipate Heat Biologics' share price to reach $22.50 in the next year. View Analyst Ratings for Heat Biologics.

Heat Biologics saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 830,219 shares, an increase of 41.0% from the April 30th total of 588,986 shares. Based on an average daily trading volume, of 6,200,249 shares, the days-to-cover ratio is currently 0.1 days. Currently, 15.3% of the company's shares are sold short.

Some companies that are related to Heat Biologics include Adamis Pharmaceuticals (ADMP), Teligent (TLGT), RedHill Biopharma (RDHL), Zynerba Pharmaceuticals (ZYNE), Acer Therapeutics (ACER), Forward Pharma (FWP), Otonomy (OTIC), ContraFect (CFRX), Genprex (GNPX), Protagonist Therapeutics (PTGX), Bellerophon Therapeutics (BLPH), BioDelivery Sciences International (BDSI), Axovant Sciences (AXON), Alpine Immune Sciences (ALPN) and Aptevo Therapeutics (APVO).

Headlines about HTBX stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heat Biologics earned a daily sentiment score of 0.07 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.56 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTBX stock can currently be purchased for approximately $2.29.

Heat Biologics has a market capitalization of $37.81 million and generates $1.51 million in revenue each year. Heat Biologics employs 19 workers across the globe.

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]